Switch theme
Sign up to access all valuation multiples
Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.
1997
17
Last FY Revenue n/a
LTM EBITDA -$20.4M
$39.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vivoryon Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$20.4M.
In the most recent fiscal year, Vivoryon Therapeutics achieved revenue of n/a and an EBITDA of -$22.9M.
Vivoryon Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vivoryon Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | -$11K | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$20.4M | XXX | -$22.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$19.4M | XXX | -$23.5M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$20.0M | XXX | -$23.1M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vivoryon Therapeutics's stock price is EUR 2 (or $2).
Vivoryon Therapeutics has current market cap of EUR 44.6M (or $50.1M), and EV of EUR 35.3M (or $39.6M).
See Vivoryon Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $39.6M | $50.1M | XXX | XXX | XXX | XXX | $-0.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vivoryon Therapeutics has market cap of $50.1M and EV of $39.6M.
Vivoryon Therapeutics's trades at -9.7x EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Vivoryon Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vivoryon Therapeutics has a P/E ratio of -2.5x.
See valuation multiples for Vivoryon Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50.1M | XXX | $50.1M | XXX | XXX | XXX |
| EV (current) | $39.6M | XXX | $39.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | -9.7x | XXX | XXX | XXX |
| EV/EBITDA | -1.9x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -2.0x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | -3529.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.5x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | -2.2x | XXX | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVivoryon Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
Vivoryon Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vivoryon Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vivoryon Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -17% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Protalix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vivoryon Therapeutics acquired XXX companies to date.
Last acquisition by Vivoryon Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Vivoryon Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vivoryon Therapeutics founded? | Vivoryon Therapeutics was founded in 1997. |
| Where is Vivoryon Therapeutics headquartered? | Vivoryon Therapeutics is headquartered in Netherlands. |
| How many employees does Vivoryon Therapeutics have? | As of today, Vivoryon Therapeutics has 17 employees. |
| Who is the CEO of Vivoryon Therapeutics? | Vivoryon Therapeutics's CEO is Dr. Ulrich Dauer. |
| Is Vivoryon Therapeutics publicy listed? | Yes, Vivoryon Therapeutics is a public company listed on AMS. |
| What is the stock symbol of Vivoryon Therapeutics? | Vivoryon Therapeutics trades under VVY ticker. |
| When did Vivoryon Therapeutics go public? | Vivoryon Therapeutics went public in 2014. |
| Who are competitors of Vivoryon Therapeutics? | Similar companies to Vivoryon Therapeutics include e.g. Julphar, Galapagos, Pharming, Armata Pharmaceuticals. |
| What is the current market cap of Vivoryon Therapeutics? | Vivoryon Therapeutics's current market cap is $50.1M |
| Is Vivoryon Therapeutics profitable? | Yes, Vivoryon Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vivoryon Therapeutics? | Vivoryon Therapeutics's last 12 months EBITDA is -$20.4M. |
| What is the current EV/EBITDA multiple of Vivoryon Therapeutics? | Current EBITDA multiple of Vivoryon Therapeutics is -1.9x. |
| What is the current FCF of Vivoryon Therapeutics? | Vivoryon Therapeutics's last 12 months FCF is -$18.3M. |
| What is the current EV/FCF multiple of Vivoryon Therapeutics? | Current FCF multiple of Vivoryon Therapeutics is -2.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
